News

AstraZeneca boost as EU approves cancer drug
It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...
AstraZeneca considers moving listing to US, the Times reports
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
AstraZeneca CEO Wants to Move Listing to US, Times Reports
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
GlobalData on MSN1d
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
Why AstraZeneca Stock Got Thumped on Thursday
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
Pharmabiz13h
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...
AstraZeneca rises Friday, outperforms market
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
AstraZeneca exit: here’s what it really means for the UK
AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...